Health Care

Amgen’s Repatha shows first‑in‑class mortality benefit in primary prevention, while the UK’s Tavneos suspension highlights rising regulatory scrutiny in the biotech sector.

HYDREIGHT TECHNOLOGIES Q2 2026: $28 M revenue, $2.5 M net profit, $3.2 M EBITDA – a capital‑pool success that boosts investor confidence and drives future acquisitions.

Explore why The Cigna Group’s steady stock, diversified insurance lineup, and new niche‑care partnership keep it in line with peers and poised for future growth.

Jiangsu Hengrui’s latest quarterly report shows strong revenue, expanding profit margins, and a robust BD strategy that fuels its oncology pipeline and positions it for international growth.

Roche boosts its oncology lineup with a $1.53B deal for Simcere’s tri‑specific antibody SIM0660, adding a potent CD79a/CD19/CD3 therapy to its antibody‑drug conjugate portfolio and partnering on TLN‑121 for lymphoma. This strategic move positions Ro…

Explore how Bayer AG’s launch of new maize and soybean “blockbuster” varieties reshapes its agribusiness strategy, boosts yields, and fuels future growth.

Explore how Intuitive Surgical’s da Vinci and Ion robotics are driving revenue growth, precision surgery, and investor confidence in the booming surgical tech market.

Abivax SA’s anti‑viral pipeline—ABX 464 for HIV and ABX 203 for hepatitis B—showcases Paris‑based biotech’s global impact on infectious disease treatment and vaccine innovation.

Teva’s TEV‑408 hits its Phase 2a primary endpoint, cutting gluten‑induced damage in celiac patients, while a $125M BioXcel deal boosts its biologic pipeline.

RenovoRx’s RenovoCath drug‑delivery system shows promise in Phase 3 TIGeR‑PaC, boosting targeted chemotherapy for pancreatic cancer and driving a new 52‑week high in shares.